Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARYAM LUSTBERG

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1639111065
CMS profile
865154
Location
COLUMBUS, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$69,375.79

71 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $61,109.85 30
Travel and Lodging $6,729.11 25
Food and Beverage $1,536.83 16

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $15,040.59 27
Bayer Healthcare Pharmaceuticals Inc. $12,044.91 14
AstraZeneca Pharmaceuticals LP $11,417.49 8
Novartis Pharma AG $7,756.00 4
Daiichi Sankyo Inc. $5,308.75 3
AstraZeneca UK Limited $4,510.00 1
Genentech USA, Inc. $3,042.05 3
Sandoz Inc. $2,880.00 2
Gilead Sciences, Inc. $2,435.68 4
Stemline Therapeutics Inc. $2,340.00 1
Caris MPI, Inc. $1,800.32 3
Eli Lilly and Company $800.00 1

Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARYAM LUSTBERG

NPI 1639111065 · CMS profile ID 865154

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

COLUMBUS, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1639111065?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARYAM LUSTBERG, NPI 1639111065, CMS profile ID 865154. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639111065?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MARYAM LUSTBERG, NPI 1639111065, CMS profile ID 865154. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639111065?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MARYAM LUSTBERG, NPI 1639111065, CMS profile ID 865154, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–71 of 71 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1639111065?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

71 matching records · $69,375.79 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 71 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–71 of 71.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bayer Healthcare Pharmaceuticals Inc. $2,142.0005/31/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1225632706 CMS
Novartis Pharma AG $700.0005/28/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1247622877 CMS
Novartis Pharma AG $1,281.0005/21/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1247622871 CMS
Daiichi Sankyo Inc. $685.0004/30/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1197003403 CMS
AstraZeneca Pharmaceuticals LP $124.9904/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206520082 CMS
Bayer Healthcare Pharmaceuticals Inc. $8,400.0003/14/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1225632708 CMS
Bayer Healthcare Pharmaceuticals Inc. $101.7003/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1225632712 CMS
Bayer Healthcare Pharmaceuticals Inc. $93.9303/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1225632714 CMS
Bayer Healthcare Pharmaceuticals Inc. $243.0003/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1225632716 CMS
Bayer Healthcare Pharmaceuticals Inc. $74.2403/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225632718 CMS
Bayer Healthcare Pharmaceuticals Inc. $101.6003/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225632720 CMS
Bayer Healthcare Pharmaceuticals Inc. $39.2903/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225632722 CMS
Bayer Healthcare Pharmaceuticals Inc. $88.0603/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225632724 CMS
Bayer Healthcare Pharmaceuticals Inc. $47.4103/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225632726 CMS
Bayer Healthcare Pharmaceuticals Inc. $101.7003/13/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1225632710 CMS
Bayer Healthcare Pharmaceuticals Inc. $348.1903/13/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1225632728 CMS
Bayer Healthcare Pharmaceuticals Inc. $134.0003/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225632730 CMS
AstraZeneca Pharmaceuticals LP $685.0003/02/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1207052294 CMS
Sandoz Inc. $2,800.0001/23/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1181970665 CMS
AstraZeneca Pharmaceuticals LP $685.0001/22/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1206295654 CMS
AstraZeneca Pharmaceuticals LP $2,740.0001/22/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1206301360 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $2,500.00 1
PY2021 $727.68 3
PY2022 $18,623.13 13
PY2023 $59,019.42 34
PY2024 $26,085.85 18
PY2025 $69,375.79 71

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,627.70 1
PY2025 Principal investigator $754,386.79 18
PY2024 Recipient $130,966.81 2
PY2024 Principal investigator $519,087.02 17
PY2023 Recipient $2,345.16 2
PY2023 Principal investigator $222,453.42 6
PY2022 Principal investigator $1,409.95 3
PY2021 Principal investigator $87,812.25 11
PY2020 Recipient $10,736.00 6
PY2020 Principal investigator $126,114.55 19
PY2019 Principal investigator $214,143.35 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

19 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $133,827.68 12/31/2025 Non-covered Recipient Entity
Yale Cancer Center
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician s Choice in Participants with HR,HER2-Unresectable Locally Advanced or Metastatic Breast Cancer No dispute reported 06/30/2026 1232923148
Principal investigator 1 Astellas Pharma Global Development $750.00 12/12/2025 Non-covered Recipient Entity
YALE CANCER CENTER
A randomized phase II study to evaluate the efficacy of fezolinetant in reducing vasomotor symptoms in women with breast cancer on endocrine therapy No dispute reported 06/30/2026 1234188251
Principal investigator 1 PFIZER INC. $22,536.51 11/13/2025 Non-covered Recipient Entity
Yale University
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228818150
Principal investigator 1 PFIZER INC. $7,286.61 10/18/2025 Non-covered Recipient Entity
Yale University
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228825758
Principal investigator 1 PFIZER INC. $2,286.61 09/13/2025 Non-covered Recipient Entity
Yale University
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228836918
Principal investigator 1 Astellas Pharma Global Development $3,500.00 08/22/2025 Non-covered Recipient Entity
YALE CANCER CENTER
A randomized phase II study to evaluate the efficacy of fezolinetant in reducing vasomotor symptoms in women with breast cancer on endocrine therapy No dispute reported 06/30/2026 1234188249
Principal investigator 1 PFIZER INC. $2,286.61 08/05/2025 Non-covered Recipient Entity
Yale University
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228841378
Principal investigator 1 PFIZER INC. $2,286.61 07/10/2025 Non-covered Recipient Entity
Yale University
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228848611
Principal investigator 1 Daiichi Sankyo Inc. $17.15 07/09/2025 Non-covered Recipient Entity
Ohio State University
DS8201-A-U301 No dispute reported 06/30/2026 1223375379
Recipient Novartis Pharmaceuticals Corporation $2,627.70 05/13/2025 Covered Recipient Physician RWE NAT Flatiron ML ROR No dispute reported 06/30/2026 1190293383
Principal investigator 1 PFIZER INC. $4,573.22 05/13/2025 Non-covered Recipient Entity
Yale University
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228856804
Principal investigator 1 PFIZER INC. $7,686.61 04/30/2025 Non-covered Recipient Entity
Yale University
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228860446
Principal investigator 1 Astellas Pharma Global Development $107,134.41 04/11/2025 Non-covered Recipient Entity
YALE CANCER CENTER
A randomized phase II study to evaluate the efficacy of fezolinetant in reducing vasomotor symptoms in women with breast cancer on endocrine therapy No dispute reported 06/30/2026 1234188247
Principal investigator 1 AstraZeneca Pharmaceuticals LP $60,991.87 02/26/2025 Non-covered Recipient Entity
YALE SCHOOL OF MEDICINE DEPARTMENT OF ORTHOPAEDICS AMD REHABILITATION
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) No dispute reported 06/30/2026 1185547215
Principal investigator 1 PFIZER INC. $2,286.61 02/21/2025 Non-covered Recipient Entity
Yale University
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228836924
Principal investigator 1 Eli Lilly and Company $5,299.40 02/10/2025 Covered Recipient Teaching Hospital
YALE-NEW HAVEN HOSPITAL
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187873603
Principal investigator 1 PFIZER INC. $2,286.61 02/04/2025 Non-covered Recipient Entity
Yale University
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228836201
Principal investigator 1 PFIZER INC. $24,540.28 01/09/2025 Non-covered Recipient Entity
Yale University
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228863917
Principal investigator 1 Eli Lilly and Company $364,810.00 01/06/2025 Non-covered Recipient Entity
YALE UNIVERSITY
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187893658